Do analysts prefer LIMN or PPBT?

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, LIMN or PPBT?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A Purple Biotech N/A N/A -$26.39M -$23.25 N/A

Is LIMN or PPBT more profitable?

Liminatus Pharma's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Purple Biotech N/A -147.77% -111.59%

Do analysts prefer SNGX or PPBT?

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SNGX or PPBT more profitable?

Purple Biotech's return on equity of -147.77% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Purple Biotech N/A -147.77% -111.59%

Do analysts recommend PPBT or LNAI?

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PPBT or LNAI more profitable?

Lunai Bioworks' return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -147.77% -111.59% Lunai Bioworks N/A N/A -1,617.76%

Does the media refer more to PPBT or LNAI?

In the previous week, Purple Biotech and Purple Biotech both had 3 articles in the media. Purple Biotech's average media sentiment score of 1.41 beat Lunai Bioworks' score of 0.61 indicating that Purple Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Purple Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lunai Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XTLB or PPBT?

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XTLB or PPBT more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Purple Biotech N/A -147.77% -111.59%

Do analysts rate XBIO or PPBT?

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Purple Biotech (PPBT) Competitors

$1.34 +0.01 (+0.75%)

As of 09:41 AM Eastern

Compare

PPBT vs. LIMN, SNGX, LNAI, XTLB, and XBIO

Should you buy Purple Biotech stock or one of its competitors? Purple Biotech's main competitors and comparable companies include Liminatus Pharma (LIMN), Soligenix (SNGX), Lunai Bioworks (LNAI), XTL Biopharmaceuticals (XTLB), and Xenetic Biosciences (XBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Purple Biotech compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, Purple Biotech had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Purple Biotech and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.79 beat Purple Biotech's score of 1.41 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Very Positive
Purple Biotech	Positive

Liminatus Pharma has a beta of 4.97, meaning that its stock price is 397% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

9.6% of Purple Biotech shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Liminatus Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

Liminatus Pharma's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Purple Biotech	N/A	-147.77%	-111.59%

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Purple Biotech beats Liminatus Pharma on 8 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Purple Biotech's return on equity of -147.77% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Purple Biotech	N/A	-147.77%	-111.59%

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Soligenix has higher revenue and earnings than Purple Biotech. Soligenix is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	44.90	-$11.08M	-$0.98	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

In the previous week, Purple Biotech had 2 more articles in the media than Soligenix. MarketBeat recorded 3 mentions for Purple Biotech and 1 mentions for Soligenix. Purple Biotech's average media sentiment score of 1.41 beat Soligenix's score of 0.91 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Soligenix	Positive
Purple Biotech	Positive

3.6% of Soligenix shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 1.9% of Soligenix shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Soligenix has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

Purple Biotech beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to Lunai Bioworks?

Purple Biotech (NASDAQ:PPBT) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Purple Biotech and Purple Biotech both had 3 articles in the media. Purple Biotech's average media sentiment score of 1.41 beat Lunai Bioworks' score of 0.61 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Purple Biotech has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Purple Biotech has higher earnings, but lower revenue than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
Lunai Bioworks	$20.94K	266.30	-$178.01M	-$0.40	N/A

Purple Biotech currently has a consensus target price of $30.00, suggesting a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lunai Bioworks' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
Lunai Bioworks	N/A	N/A	-1,617.76%

Summary

Purple Biotech beats Lunai Bioworks on 9 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to XTL Biopharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Purple Biotech had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Purple Biotech and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.79 beat Purple Biotech's score of 1.41 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Very Positive
Purple Biotech	Positive

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XTL Biopharmaceuticals has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than Purple Biotech. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	10.72	-$6.97M	-$0.64	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Purple Biotech	N/A	-147.77%	-111.59%

Summary

XTL Biopharmaceuticals beats Purple Biotech on 8 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Xenetic Biosciences has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 2,155.64%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Purple Biotech has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Purple Biotech	N/A	-147.77%	-111.59%

Xenetic Biosciences has higher revenue and earnings than Purple Biotech. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26M	1.50	-$2.68M	-$1.16	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

In the previous week, Purple Biotech had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for Purple Biotech and 2 mentions for Xenetic Biosciences. Purple Biotech's average media sentiment score of 1.41 beat Xenetic Biosciences' score of 1.39 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenetic Biosciences	Positive
Purple Biotech	Positive

Summary

Xenetic Biosciences beats Purple Biotech on 8 of the 15 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.29M	$3.93B	$7.25B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	22.58%
P/E Ratio	-0.06	13.62	275.60	26.13
Price / Sales	N/A	1,184.16	583.42	81.43
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	0.13	17.24	10.83	6.16
Net Income	-$26.39M	-$22.69M	$3.50B	$381.12M
7 Day Performance	-14.10%	-1.59%	-1.25%	-1.46%
1 Month Performance	-22.09%	-7.92%	-4.02%	-3.37%
1 Year Performance	-77.29%	14.22%	7.14%	1.49%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	3.2996 of 5 stars	$1.34 +0.8%	$30.00 +2,138.8%	-77.5%	$1.29M	N/A	N/A	10	News Coverage Positive News Short Interest Decrease Gap Up
LIMN Liminatus Pharma	0.9598 of 5 stars	$3.70 -7.3%	N/A	-94.7%	$5.36M	N/A	N/A	1
SNGX Soligenix	1.1325 of 5 stars	$0.36 -0.3%	N/A	-78.4%	$5.32M	$120K	N/A	14
LNAI Lunai Bioworks	0.3984 of 5 stars	$1.13 -0.9%	N/A	-86.4%	$5.17M	N/A	N/A	29	Gap Down
XTLB XTL Biopharmaceuticals	0.8142 of 5 stars	$2.01 -7.8%	N/A	N/A	$5.16M	$450K	N/A	10	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. LIMN, SNGX, LNAI, XTLB, and XBIO

How does Purple Biotech compare to Liminatus Pharma?

Summary

How does Purple Biotech compare to Soligenix?

Summary

How does Purple Biotech compare to Lunai Bioworks?

Summary

How does Purple Biotech compare to XTL Biopharmaceuticals?

Summary

How does Purple Biotech compare to Xenetic Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. LIMN, SNGX, LNAI, XTLB, and XBIO

How does Purple Biotech compare to Liminatus Pharma?

Does the media refer more to LIMN or PPBT?

Which has more risk & volatility, LIMN or PPBT?

Do insiders and institutionals have more ownership in LIMN or PPBT?

Which has stronger valuation & earnings, LIMN or PPBT?

Is LIMN or PPBT more profitable?

Do analysts prefer LIMN or PPBT?

Summary

How does Purple Biotech compare to Soligenix?

Is SNGX or PPBT more profitable?

Do analysts prefer SNGX or PPBT?

Which has higher valuation and earnings, SNGX or PPBT?

Does the media favor SNGX or PPBT?

Do institutionals & insiders hold more shares of SNGX or PPBT?

Which has more volatility & risk, SNGX or PPBT?

Summary

How does Purple Biotech compare to Lunai Bioworks?

Do insiders and institutionals have more ownership in PPBT or LNAI?

Does the media refer more to PPBT or LNAI?

Which has more volatility & risk, PPBT or LNAI?

Which has stronger valuation & earnings, PPBT or LNAI?

Do analysts recommend PPBT or LNAI?

Is PPBT or LNAI more profitable?

Summary

How does Purple Biotech compare to XTL Biopharmaceuticals?

Do institutionals & insiders believe in XTLB or PPBT?

Does the media favor XTLB or PPBT?

Do analysts recommend XTLB or PPBT?

Which has more volatility and risk, XTLB or PPBT?

Which has stronger valuation & earnings, XTLB or PPBT?

Is XTLB or PPBT more profitable?

Summary

How does Purple Biotech compare to Xenetic Biosciences?

Which has more volatility and risk, XBIO or PPBT?

Do insiders and institutionals have more ownership in XBIO or PPBT?

Do analysts rate XBIO or PPBT?

Is XBIO or PPBT more profitable?

Which has stronger earnings and valuation, XBIO or PPBT?

Does the media refer more to XBIO or PPBT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools